多西紫杉醇联合顺铂一线治疗不能手术的非小细胞肺癌  

First-line chemotherapy of docetaxel/cisplatin for unresectable non-small cell lung cancer

作　　者：周彩存[1] 郑迪[1] 张捷[1] 鲁冰[1] 吕梅君[1] 徐建芳[1] 

机构地区：[1]上海市肺科医院肿瘤科,上海200433

出　　处：《临床肿瘤学杂志》2004年第1期8-10,共3页Chinese Clinical Oncology

摘　　要：目的 :探讨多西紫杉醇 (泰素帝 )联合顺铂 4周方案一线治疗不能手术切除的非小细胞肺癌 (NSCLC)的疗效与安全性。方法 :经病理组织学或细胞学确诊的ⅢB或Ⅳ期NSCLC患者 39例 (男 2 1例 ,女 18例 ) ,年龄在 33～ 79岁 ,ECOG评分为 0～ 2分 ;均予静脉滴注泰素帝和顺铂各 75mg/m2 ,第 1天 ,每 4周重复。 2周期后评价疗效与毒副反应 ,并随访生存期。结果 :38例可评价患者中 ,部分缓解 (PR) 2 1例 ,完全缓解 (CR) 1例 ,进展 (PD) 4例 ;总体有效率为 5 8%。ECOG评分 0～ 1分患者有效率明显高于ECOG评分 2分的患者。中位生存期为 14个月 ,1年生存率为 6 1 5 %。Ⅲ度或Ⅳ度白细胞减少症发生率为39 %。 1例因白细胞减少症 ,伴发感染而死亡 ;其它副作用轻微。结论 :多西紫杉醇联合顺铂Objective:To investigate effects and safety of docetaxel/cisplatin given as first-line chemotherapy every 4 weeks in unresectable non-small cell lung cancer (NSCLC). Methods:Thirty-nine patients (male/female: 21/18) with unresectable NSCLC were enrolled for the study. They were at the ages ranging from 33 to 79 years old with ECOG PS of 0～2. Docetaxel and cisplatin were administered at the dose of 75 mg/m 2 on day 1 intravenously every 4 weeks. The responses and toxicity of chemotherapy were evaluated every two cycles and survival was followed up.Results:In the 38 evaluable cases, partial response (PR) and complete response (CR) were observed in 21 cases and 1 case, respectively with overall response rate of 58%. The response rate in the cases with ECOG PS of 0～1 was significantly higher than in those with ECOG PS of 2. Median survival time was 14 months and 1 year-survival rate was 61 5%. The toxicities were mild, including 40% Grade 3 or 4 leucopenia. One case died from leucopenia infection soon after 1 cycle of chemotherapy. Conclusion:Four-week regimen of docetaxel/cisplatin was effective and safe as the first line treatment for the unresectable NSCLC patients.

关 键 词：多西紫杉醇 顺铂 治疗 手术 非小细胞肺癌 肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]